Cerebrolysin
$211.00
-
Delivery guarantee Reshipped free if it doesn't arrive
-
≥99% purity Manufacturer-direct production
-
Independent COAs View COAs for this product →
-
Store credit guarantee Send any COA result, get store credit
Cerebrolysin - Neurotrophic Peptide Preparation Research Compound
Cerebrolysin is a porcine-brain-derived peptide preparation developed by Ever Pharma (Austria) and approved in more than 50 countries for neurological indications including stroke, traumatic brain injury, and vascular dementia. It is not a single molecule - Cerebrolysin is a standardized mixture of low-molecular-weight peptides and free amino acids produced by enzymatic hydrolysis of purified porcine brain proteins. In the research-peptide toolkit, it is the reference “neurotrophic factor mimetic” - a preparation that produces BDNF-, NGF-, and GDNF-like signaling without any single dominant active component.
Why Cerebrolysin’s Multi-Component Profile Matters
Most research peptides are defined by a single amino-acid sequence targeting a single receptor. Cerebrolysin is different - it contains multiple low-molecular-weight peptide fragments that collectively mimic the signaling profile of several endogenous neurotrophins. The published clinical and preclinical literature tracks BDNF-pathway activation, neuronal survival, synaptic plasticity, and post-ischemic recovery endpoints. That breadth is why Cerebrolysin sits alone in the “neurotrophic preparation” category rather than in the standard single-target peptide categories.
| Pathway | What it does in plain terms |
|---|---|
| BDNF-like signaling | Supports neuronal survival and synaptic plasticity |
| NGF / GDNF mimetic activity | Broad neurotrophic signaling not limited to a single factor |
| Neuronal apoptosis | Reduced in post-ischemic and TBI models |
| Excitotoxic stress | Attenuated in published preclinical work |
Cerebrolysin vs Single-Peptide Nootropics
Cerebrolysin is often compared to single-peptide nootropic compounds (Semax, Selank, Dihexa, P21). The comparison is imperfect because Cerebrolysin is a multi-component preparation, not a single sequence.
| Compound | Type | Primary activity |
|---|---|---|
| Cerebrolysin | Porcine brain hydrolysate (multi-peptide) | BDNF/NGF-like neurotrophic signaling |
| Semax | Single synthetic heptapeptide | BDNF upregulation; ACTH (4-10) analog |
| Selank | Single synthetic heptapeptide | Tuftsin analog; anxiolytic / immune-modulatory |
Research Applications
Cerebrolysin is used in studies examining:
- Post-ischemic and stroke-recovery endpoints
- Traumatic brain injury (TBI) models
- Vascular dementia and cognitive-decline research
- BDNF, NGF, and GDNF-pathway activation
- Synaptic plasticity and neuronal survival endpoints
- Comparative nootropic research vs. single-peptide compounds
Specifications
| Format | Sterile aqueous solution |
| Purity | ≥99% |
| Aliases | FPE 1070, porcine brain hydrolysate, neurotrophic peptide preparation |
| Available sizes | 60mg |
| Storage | 2-8°C; stable 12+ months |
| Use | Research purposes only - not for human use |
Storage & Handling
Cerebrolysin ships as a sterile solution rather than as a lyophilized powder. Unopened vials are kept at 2-8°C under standard cold-chain conditions. Handling and stability parameters for Cerebrolysin are documented in the published peer-reviewed literature.
Reference Literature
Published clinical and preclinical Cerebrolysin literature is available through PubMed, Google Scholar, and other peer-reviewed databases. WWP does not provide protocol design, dosing guidance, or administration parameters. Those decisions rest with the researcher and any applicable institutional review board.
Common Questions About Cerebrolysin Research
What is Cerebrolysin?
It is a standardized mixture of low-molecular-weight peptides and free amino acids produced by enzymatic hydrolysis of purified porcine brain proteins. It mimics the signaling profile of several endogenous neurotrophic factors (BDNF, NGF, GDNF) rather than acting as a single-sequence peptide.
How does Cerebrolysin compare to Semax?
Cerebrolysin is a multi-peptide preparation; Semax is a single synthetic heptapeptide (ACTH 4-10 analog). Both appear in BDNF-pathway literature, but Semax has a defined single sequence and Cerebrolysin does not. They are studied in overlapping but not interchangeable research contexts.
Is Cerebrolysin FDA approved?
No. Cerebrolysin is not FDA approved in the United States. It is approved in more than 50 other countries for stroke, TBI, and vascular dementia. Every vial WWP ships is labeled and sold strictly for laboratory and research use only.
Why is Cerebrolysin not approved in the US?
Cerebrolysin has never completed a US-specific FDA approval pathway. The published clinical program is international and does not include the regulatory filings the FDA requires. It remains an approved neurological drug in Europe, Asia, and Latin America.
How is Cerebrolysin stored?
Unopened vials are kept at 2-8°C under standard cold-chain conditions. Stability and handling parameters for Cerebrolysin are documented in the published peer-reviewed literature.
Purity Guarantee
Every batch is ≥99% purity. Send us a COA from any independent test and we’ll issue store credit regardless of what it shows.
-
MOTS-c
Price range: $122.00 through $384.00 Select options This product has multiple variants. The options may be chosen on the product page -
GHK-Cu
Price range: $88.00 through $153.00 Select options This product has multiple variants. The options may be chosen on the product page -
NAD+
Price range: $146.00 through $323.00 Select options This product has multiple variants. The options may be chosen on the product page -
CJC-1295 No DAC / Ipamorelin
Price range: $253.00 through $357.00 Select options This product has multiple variants. The options may be chosen on the product page